BioMed X and Novo Nordisk Team Up to Transform Oral Peptide Delivery

BioMed X and Novo Nordisk Team Up to Transform Oral Peptide Delivery

By, Admin 22 August 2025

BioMed X, the Heidelberg-based research institute, has announced a new collaboration with Novo Nordisk. The mission? Crack one of pharma’s toughest challenges: making peptide drugs work better when taken orally.

Right now, most peptide-based therapies struggle with:

  • Low absorption in the gut.
  • Rapid digestion and clearance.
  • Poor patient convenience compared to injectables.

This project aims to change all that.

The New Project: Prolonged Retention in the Gut

The initiative is called: “Prolonged Retention of Oral Peptide Formulations in the Gut.”

Here’s the goal in plain English:

  • Develop tablets or capsules that stick around longer in the small intestine.
  • Release the drug gradually for better absorption.
  • Improve bioavailability without compromising gut safety.

If successful, this could make peptide drugs like GLP-1 agonists—currently reshaping diabetes and obesity treatment—more effective and easier to take.

Why Oral Peptides Are So Hard

Despite decades of research, oral peptides face huge barriers:

  • The intestine clears drugs too fast.
  • Peptides don’t easily cross intestinal walls.
  • Formulations often fail before absorption can happen.

This new project tackles these problems head-on with novel retention technologies.

Voices from the Leaders

Dr. Christian Tidona, CEO of BioMed X, said it best:

“Making peptide drugs orally available via new technologies will have a major impact on patients’ lives.”

From Novo Nordisk, Stephen Buckley added:

“We launched the first oral biologic on the market. Now, we want to push the boundaries even further.”

The Opportunity for Researchers

BioMed X is calling for global talent. Scientists interested in joining this initiative can submit proposals by October 12, 2025 through the BioMed X Career Space.

This is a rare chance to work at the intersection of:

  • Industry and academia.
  • Basic science and drug development.
  • Cutting-edge formulation and real-world impact.

The Bigger Picture

Why does this matter? Because oral delivery could:

  • Increase patient compliance (no injections).
  • Expand access to life-changing therapies.
  • Redefine how chronic conditions like diabetes and obesity are treated.

With BioMed X’s crowdsourcing model and Novo Nordisk’s track record in diabetes innovation, this partnership has the potential to accelerate breakthroughs.

Final Takeaway

If they succeed, peptide therapies may finally move from syringes to simple pills. For patients, that’s not just convenience—it’s freedom.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!